Study of tagraxofusp reports 90 percent response rate for deadly blood cancer with no prior available therapies
An open-label, multi-cohort Phase II trial, led by investigators at The University of Texas MD…
Browsing: tagraxofusp
Trending
- Making Telehealth Human – Podcast
- Sign Up for The Oncology Newsletter | Our free weekly news roundup
- AACR 2021: Neoadjuvant nivolumab plus chemotherapy increased pathological complete response rate in CheckMate-816 lung cancer trial
- AACR 2021: Unselected autologous tumour infiltrating lymphocyte therapy shows early promise in patients with metastatic melanoma
- AACR 2021: Novel approach to PRMT5 inhibition that selectively targets the PRMT5/MTA complex in MTAP-deleted cancer models
- AACR 2021: FDA-approved selpercatinib shows clinical benefits for RET fusion-positive cancers beyond lung and thyroid cancers
- AACR2021: Early-onset colorectal cancers – patients of different races
- AACR 2021: Level of chromosomal abnormality in lung cancer may predict immunotherapy response
- AACR 2021: Personalised cancer vaccine given after adjuvant therapy safe, shows early efficacy in multiple tumour types
- AACR 2021: CREB1 identified as potential therapeutic target for the treatment of pancreatic cancer
